Fibrokolium in the treatment of irritable bowel syndrome with constipation: the first experience in Ukraine
Journal Title: Сучасна гастроентерологія - Year 2018, Vol 0, Issue 5
Abstract
Objective — to compare the clinical efficacy of Fibrokolium (Specchiasol S.r.l, Italy) with the drug psyllium in the treatment of patients with irritable bowel syndrome and constipations (IBS-C). Materials and methods. The simple open study involved 34 patients with IBS-C. The diagnosis was set on the basis of the IV Rome diagnostic criteria. Among the patients, 29 women prevailed (72.5 %), the average age of the patients was 37.4 ± 5.2 years. The patients were divided into 2 gender- and age-matched groups: 12 subjects of the first group received Fibrokolium in a dose of 1 powder with 200 ml of water twice a day; 22 patients of the second group were administered psyllium in a dose of 1 powder (5 g) twice a day with a sufficient amount of water. All patients discontinued the intake of laxatives, spasmolytics and prokinetics 10 days before the start of investigative treatment. At the baseline and on the 14th day of therapy all patients undergone the measurements of the bowel movements frequency, the form of feces according to the Bristol scale, the severity of flatulence by ultrasound accessibility coefficient (UAC), the severity of abdominal pain according to the visual analogue scale (VAS) and the time of intestinal (oral-anal) transit were determined with carbolene probe. Results. After 2 weeks of treatment in the first group, 10 patients (84 %) had normal stools of 3— 6 types, one (8 %) had 7 type, and another one (8 %) had 2 type. In the second group, stools type 3—6 was achieved in 16 patients (73 %), type 7—8 in 2 (9 %) and in 4 (18 %) 1—2 types. The frequency of bowel movements in the first group increased by 95 % up to 3.7 ± 0.34 times a week, and in the second group by 94 % up to 3.5 ± 0.33 times a week. Intestinal transit time in the first group decreased by 31 % up to 58.6 ± 16.5 hours, in the second by 24 % up to 71.2 ± 18.9 hours. The UAC values in the first group increased by 28 % up to 51.2 ± 7.1 %, in the second by 10 % up to 49.7 ± 6.9 %. The pain severity as per VAS score decreased in the first group by 33 % up to 5.2 ± 1.1 cm, and in the second by 10 % up to 6.6 ± 1.4 cm. All differences between the groups were not statistically significant (р > 0.05). In both groups such adverse effects as profuse diarrhea, electrolyte disorders and changes in biochemical parameters were not revealed. The complaints on abdomen heaviness feeling after the drug administration, not requiring the treatment discontinuation, was reveled in one patients from the first group and two patients from the second. Conclusions. Fibrokolium, containing psyllium, tamarind, ginger, and plant enzymes is just as effective in eliminating constipation in patients with IBS, as was the psyllium preparation used for comparison. Due to the additional herbal components, Fibrokolium safely and more effectively reduced the severity of flatulence and pain in patients with IBS-C.
Authors and Affiliations
A. E. Dorofeyev, M. M. Rudenko, T. P. Snisarevska
Keywords
Related Articles
- EP ID EP418350
- DOI 10.30978/MG-2018-5-81
- Views 112
- Downloads 0
The syndrome of increased intestinal permeability: a focus on microbiota
The literature data have been presented regarding the syndrome of increased intestinal permeability, the role of intestinal; dysbiosis in the development of the increased intestinal permeability and its effects on the de...
Non-alcoholic fatty liver disease in the context of the gut microbiome
The article presents modern views on the epidemiological situation with the non-alcoholic fatty liver disease (NAFLD) in the world, its prevalence among the population of European countries, and gender-associated charact...
Modern approaches to the treatment of patients with functional constipation
Objective — to study the efficacy and tolerability of the Lactofor® complex (Ananta Medicare) in outpatients with the verified diagnosis of functional constipation (FC) according to Rome criteria IV. Materials and metho...
Non-invasive diagnosis of non-alcoholic fatty liver disease: the available opportunities we have today
Non-alcoholic fatty liver disease (NAFLD) is becoming an increasingly common disease, it is currently diagnosed in more than a quarter of adult population worldwide, and its portion in the overweight patients with type 2...
The use of proton pump inhibitors in the general clinical practice: advantages and disadvantages
The article presents modern views on the use of proton pump inhibitors in clinical practice with account of the patients’ age, therapyduration and comorbidity. The analysis has been performed for the literature data and...